Zentalis Pharmaceuticals recently reported completing Part 2a enrollment in its DENALI trial, aligning with the FDA on the Phase 3 ASPENOVA design for azenosertib and outlining expectations for dose ...
Source LinkZentalis Pharmaceuticals recently reported completing Part 2a enrollment in its DENALI trial, aligning with the FDA on the Phase 3 ASPENOVA design for azenosertib and outlining expectations for dose ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.